Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on May 09, 2022 12:40pm
114 Views
Post# 34667406

RE:RE:RE:ASCO June 3-7

RE:RE:RE:ASCO June 3-7Well, I am just confused. I did say AACR at first and there is good chance that is what Christian said. But then I thought, AACR happened already in April, so I mis-heard him when he said ASCO. Now, I suspect, he didsay AACR and I just was unaware of the October AACR conference and thought he must have meant ASCO. From a timing perspective, the October conference seems to be what he was likely referring to as they will have some good phase 1b data by then too. So, he likely did say AACR and I was just unaware of what he was actually referring to. 

Will they have anything at ASCO? Now I am not so sure.

qwerty22 wrote:

You said AACR  first time around. This event seems exactly on topic but it isn't until Oct.

https://event.eortc.org/ena2022/

 

qwerty22 wrote:

 

Seems impossible to get a late breaker. Are you sure Christian had this conference in mind?

https://conferences.asco.org/am/late-breaking-data-submission-guidelines

 

SPCEO1 wrote: I thought the ASCO conference (finally remembered the name of it) was in late June but it is actually in early June. So, a late breaker presentation there would certainly fit from a timing prespective but there might not be enough time to pull that off. I also wonder how often a phase 1a would be even considered for a late breaker - probably not too often I would imagine. They may be hustling just to get any data put together for this conference. But  if they can pull it off, we will not have to wait as long as I thought we would to hear any good news they share about phase 1a data.

 

 





<< Previous
Bullboard Posts
Next >>